Hepatoprotective drugs for prevention of liver injury resulting from anti-tuberculosis treatment:A meta-analysis of cohort studies  

作　　者：Dong Wang Xiao-ling Cai Xu Lin Jing Zheng Yun-li Wu Xian-e Peng 

机构地区：[1]Department of Epidemiology and Health Statistics,Fujian Provincial Key Laboratory of Environment Factors and Cancer,School of Public Health,Fujian Medical University,Fuzhou,China [2]Department of General Surgery(Emergency Surgery),Fujian Medical University Union Hospital,Fuzhou,China [3]Key Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,School of Basic Medical Sciences,Fujian Medical University,Fuzhou,China [4]Department of Respiratory and Critical Care Medicine,Fuzhou Pulmonary Hospital of Fujian,Educational Hospital of Fujian Medical University,Fuzhou,China

出　　处：《Infectious Medicine》2022年第3期154-162,共9页感染医学（英文）

基　　金：supported by grants from the National Natural Science Foundation of China(grant number 82172249);the Natural Science Foundation of Fujian Province(No.2019J01316,2020J01607).

摘　　要：Background:The incidence of liver injury caused by anti-tuberculous(TB)drugs is very high.However,owing to a lack of sufficient evidence,preventive use of hepatoprotective drugs is not yet recommended.Therefore,we aimed to assess the protective effect of hepatoprotective drugs for anti-TB drug-induced liver injury.Methods:We conducted a literature search in China Biology Medicine disc,China National Knowledge Infras-tructure,WanFang,Chinese Scientific and Technological Journal,PubMed,Cochrane Library,Web of Science,and Embase.We performed meta-analysis using R 4.0 and Review Manager 5.3 software.Results:A total of 18 studies involving 3589 patients from 2 groups were included.Use of hepatoprotective drugs contributed to a lower incidence of liver injury as compared with conventional anti-TB treatment alone(relative risk[RR]=0.39,95%confidence interval[CI]:0.28-0.53,p<0.001).In subgroup analysis,significant protective effects were noted for mild liver injury(RR=0.30,95%CI 0.15-0.58),moderate(or severe)liver injury(RR=0.35,95%CI 0.19-0.65),and liver injury within 2-4 weeks(RR=0.37,95%CI 0.19-0.71).We also found a statistically significant difference in the incidence of drug withdrawal(RR=0.58,95%CI 0.34-0.97,p=0.040).Conclusions:Our results demonstrate that hepatoprotective drugs are effective in preventing liver injury in pa-tients receiving anti-TB treatment,to some extent.

关 键 词：Hepatoprotective drug TUBERCULOSIS Liver injury META-ANALYSIS 

分 类 号：R575[医药卫生—消化系统]